Cardiomyopathy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Market Overview

The global cardiomyopathy market reached US$ 1.90 billion in 2023 and is expected to reach US$ 3.02 billion by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

Cardiomyopathy is a progressive disease of the heart muscle or myocardium, that makes it harder for the heart to pump blood to the rest of the body. It can lead to an irregular heartbeat, heart failure, or other complications.

There are various types of cardiomyopathy. The main types include dilated, hypertrophic, and restrictive cardiomyopathy. Treatment includes medicines and sometimes surgically implanted devices and heart surgery. Some people with severe cardiomyopathy need a heart transplant. Treatment depends on the type of cardiomyopathy and the severity of the disease.

Market Scope

To know more insights – Download free Sample

Market Dynamics: Drivers

Rising Prevalence of Heart Diseases & Awareness Programs

The demand for the global cardiomyopathy market is driven by multiple factors. One of the key driving factors is the rising prevalence of heart diseases & awareness programs. Cardiomyopathy is a disease of the heart muscle that can occur at any age and can be passed down genetically. It affects around 1 in every 250 people worldwide, is an important cause of heart failure, and is the leading reason for needing a heart transplant.

According to Heart Disease and Stroke Statistics in January 2023, in the United States, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the United States, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%).

In addition, key players in the market initiations, innovative launches,  and awareness programs would propel this market growth. For instance, in June 2024, Global Heart Hub (GHH), the international alliance of heart patient organizations, launches its Cardiomyopathy Awareness Campaign, along with cardiomyopathy patient organizations across the globe.

Also, in October 2022, the Health Minister launched Congenital Heart Disease Research Program. This program creates new academic partnerships that will drive innovative research to enhance the delivery of evidence-based and cost-effective cardiac care to children and young people across the island of Ireland.

Similarly, In August 2023, Lupin Digital Health (LDH), India’s leading cardiac digital therapeutics company, announced the launch of its newest offering, LyfeTM Digital Heart Failure Clinic in India. This groundbreaking e-clinic aims to help cardiologists and caregivers manage heart failure patients effectively from the comfort of their homes.

Restraints

Factors such as the high cost of diagnosis & treatment, lack of skilled professionals, lack of awareness among people, limited treatment options, and stringent regulatory framework, are expected to hamper the market.

Segment Analysis

The global cardiomyopathy market is segmented based on type, treatment, end-user, and region.

The dilated cardiomyopathy segment accounted for approximately 53.3% of the  global cardiomyopathy market share

The dilated cardiomyopathy segment is expected to hold the largest market share over the forecast period. Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. 

A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.

Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. 

The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart disease has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

In addition, the market players are investing in research and development to conduct new treatment drugs for dilated cardiomyopathy. As per Northwestern Medicine news in May 2023, say that an increase in early cardiovascular screenings for dilated cardiomyopathy. An informational communications tool provided to patients with dilated cardiomyopathy helped increase cardiovascular screenings in their first-degree relatives who have a higher risk of developing the genetic disease.

Moreover, key players' strategies such as partnerships & collaboration, and innovative technologies would propel this market growth. In 2022, Renovacor, Inc. announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA), and the American Association of Heart Failure Nurses (AAHFN). The company will provide sponsorship for initiatives to raise awareness of cardiomyopathies and to educate the patient and provider communities about the importance of genetic testing for patients and families living with DCM.

Also in, February 2024, CU Anschutz Set to launch gene therapy trials for heart disorders. Three decades of dilated cardiomyopathy research leads to an innovative study. There are several different approaches, and the approach that is going to be used is a direct injection through an infusion. In patients with a genetic defect, gene therapy delivers a correct and working copy of the gene to essentially fix or replace that damaged gene.

Geographical Analysis

North America accounted for approximately 42.1% of the global cardiomyopathy  market share 

North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of heart diseases one of the key factors driving the market.

The American Heart Association released Heart and Stroke Statistics in 2022, cardiac arrest remains a public health crisis. There are more than 356,000 out-of-hospital cardiac arrests (OHCA) annually in the U.S., nearly 90% of them fatal. The incidence of EMS-assessed non-traumatic OHCA in people of any age is estimated to be 356,461, or nearly 1,000 people each day. Survival to hospital discharge after EMS-treated cardiac arrest languishes at about 10%.

Similarly, a research study published in NCBI in January 2022 that hypertrophic cardiomyopathy is the most common genetic heart disease in the US, with an estimated prevalence of 1 in 500.

Moreover, in this region, major key players' presence, well-developed healthcare infrastructure, government awareness programs, and funding initiatives help to drive this market growth. for instance, in May 2022, the HealthWell Foundation an independent non-profit that provides a financial lifeline for inadequately insured Americans, announced that it has opened a new fund to assist individuals living with cardiomyopathy. 

Through the new fund, HealthWell will provide up to $10,000 in medication copayment or insurance premium assistance for a 12-month grant period to eligible Medicare patients who have annual household incomes up to 500 percent of the federal poverty level.

Also, in November 2021, Bristol Myers Squibb launched Could It Be HCM? Campaign to increase awareness of hypertrophic cardiomyopathy (HCM), the most common inherited heart disease reported prevalence of HCM ranges from 1 in 200 to 1 in 500† people in the general population, however, it is estimated that many patients remain undiagnosed, underscoring the need for increased awareness and education.

Moreover, major players in the industry introducing new drug approvals would drive this market. For instance, in June 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. 

Camzyos is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM.

Market Segmentation

 By Type 

• Dilated Cardiomyopathy
• Hypertrophic Cardiomyopathy
• Restrictive Cardiomyopathy
• Arrhythmogenic Right Ventricular Dysplasia
• Transthyretin Amyloid Cardiomyopathy

 By Treatment 

• Medication
• Surgically Implanted Device
• Implantable Cardioverter-Defibrillator
• Ventricular Assist Device
• Cardiac Resynchronization Therapy Device
• Pacemaker
• Non-surgical procedure
• Septal Ablation
• Radiofrequency Ablation
• Surgery
• Septal Myectomy
• Heart Transplant

 By End User 

• Hospital
• Ambulatory Surgical Centers
• Others

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe
• South America
• Brazil
• Argentina
• Rest of South America
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the cardiomyopathy market include Abbott, Bristol Myers Squibb, AstraZeneca, Novartis AG, Boehringer Ingelheim International GmbH, bioMérieux SA, Bio-Rad Laboratories, Inc, Merck & Co., Inc, Pfizer Inc, and Sanofi among others.

Key Developments

• In April 2024, Roche Diagnostics India announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF).
• On May 31, 2024, MarinHealth Medical Center announced the expansion of its cardiac care services with the introduction of its cardiac magnetic resonance imaging (MRI) tool.
• In July 2023, Bridgebio Pharma announced consistently positive results from the phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy.
• In February 2023, Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).
• On April 2022, Bristol Myers bags FDA nod for blockbuster-to-be cardio drug Camzyos. Camzyos is a green light to treat symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM).

Why Purchase the Report?

• To visualize the global cardiomyopathy market segmentation based on type, treatment, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global cardiomyopathy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global cardiomyopathy market report would provide approximately 62 tables, 63 figures, and 182 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies